Manaʻo ʻia ʻeono Peptides: He aha ka Iulai 2026 ʻO nā koho aʻoaʻo no ka mākaukau hōʻike

Pane wikiwiki

The Pharmacy Compounding Advisory Committee's July 2026 vote on seven peptides looked decisive in headlines and was not decisive in law. FDA's own staff scient…

He aha ka mea i koho maoli ai ke komite aʻoaʻo FDA, a ke hoʻololi nei ke koho i kekahi mea?

Kūʻai nui ʻo Eptides Peptide Maoli Ua ʻōlelo ke komite i ʻeono o ʻehiku mau peptides i koho ʻia no ka Pauku 503A Bulks List, a ʻaʻole hoʻololi ka balota i ke kūlana kānāwai ma kona iho. ʻO nā mea ʻeono he BPC-157, KPV, TB-500, c-HUAOLELO, Semax a me Epitalon; emideltide, kapa ʻia ʻo DSIP, ʻaʻole ʻōlelo ʻia (ke komite o Iulai 2026 mooolelo halawai). Ua māhele ʻia ka hālāwai i ʻelua lā, me nā mea ʻehā i lohe ʻia ma 23 Iulai a ʻekolu ma 24 Iulai, a ua maheleia na balota apau (ka §503A alahele kālailai).

<papa helu ="blog-chart" kaila="laula-nui:640px;palena palena:1.5rem auto;nui-momona:12px;kiʻekiʻe laina:1.3;kala kala:hooilina"> <svg viewBox="0 0 560 380" kaila="laula-nui: 100%; kiekie: kaʻa; font-ohana: 'Inter', ʻōnaehana-ui, sans-serif; kala kala: #1e293b; --pakuhi-muted: #64748b;" kuleana="img" aria-labelledby="pcac-vote-tail-by-peptide-title pcac-vote-tallies-by-peptide-desc"> <kaila> /* Hoʻokomo ka mea hāʻawi i ka pakuhi i loko o kahi iframe nona ka ʻeleʻele ʻeleʻele, a he ʻano ʻokoʻa ka iframe i ka pakuhi, no laila ua hōʻike ʻia nā pahu pahu leka me he mau papa ʻeleʻele a puni (prod 09-22). Akaka ka palapala i loko o ka iframe ma ka paʻamau; ʻO ka pena kiʻi ma ʻaneʻi e uhi ana i ke kāʻei o ka element, a ke kau ʻia ka pakuhi, ʻaʻohe mea pili kēia. E mālama i nā pale kihi ma waho o kēia poloka: ʻO kahi mea ʻano i loko o kahi SVG i hoʻokaʻawale ʻia ma ke ʻano he ʻike haole, no laila, hoʻolei kekahi bracket hele i kēlā me kēia lula i loko. */ html, kino { hope: #ffffff; palena palena: 0; } @media (makemake-hoemi-holo: hoemi) { * { hoʻouluulu: ʻaʻohe !mea nui; hoʻololi: ʻaʻohe !mea nui; } } </kaila> <pololei x="0" y="0" laula="560" kiekie="380" rx="8" hoʻopiha="#ffffff" /> <inoa id="pcac-vote-talies-by-peptide-title">Ua helu ʻia nā koho balota PCAC e ka peptide</inoa> <wehewehe id="pcac-vote-talies-by-peptide-desc">Ua helu ʻia nā koho balota PCAC e ka peptide, e like me ka manao mai ke kumu i oleloia. Ua helu ʻia nā koho balota PCAC e ka peptide. ʻikepili pā hui: BPC-157: No ka mea 8, Kūʻē 6, E hoole 1; KPV: No ka mea 8, Kūʻē 6, E hoole 1; TB-500: No ka mea 8, Kūʻē 6, E hoole 1; c-HUAOLELO: No ka mea 7, Kūʻē 5, E hoole 2; Mai hoʻolohe: No ka mea 8, Kūʻē 5, E hoole 1; Epitalona: No ka mea 7, Kūʻē 4, E hoole 1; Emideltide: No ka mea 6, Kūʻē 7, E hoopau i ka 1. Source: Bass Berry & ʻO Sims, makaʻala o ka mea kūʻai aku ma ke koho pāloka PCAC 2026-07-31.</wehewehe> <kikokikona x="280.0" y="29" heleuma kikokikona="waena" font-size="18" font-kaumaha="800" hoʻopiha="kala kala">Ua helu ʻia nā koho balota PCAC e ka peptide</kikokikona> <laina x1="72" y1="277.0" x2="492" y2="277.0" hahau ="kala kala" opacity="0.08" /> <laina x1="72" y1="230.8" x2="492" y2="230.8" hahau ="kala kala" opacity="0.08" /> <laina x1="72" y1="184.5" x2="492" y2="184.5" hahau ="kala kala" opacity="0.08" /> <laina x1="72" y1="138.2" x2="492" y2="138.2" hahau ="kala kala" opacity="0.08" /> <laina x1="72" y1="92.0" x2="492" y2="92.0" hahau ="kala kala" opacity="0.08" /> <kikokikona x="66" y="281.0" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">0</kikokikona> <kikokikona x="66" y="234.8" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">2.5</kikokikona> <kikokikona x="66" y="188.5" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">5</kikokikona> <kikokikona x="66" y="142.2" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">7.5</kikokikona> <kikokikona x="66" y="96.0" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">10</kikokikona> <pololei x="72.0" y="62" laula="10" kiekie="10" hoʻopiha="#f97316" /> <kikokikona x="87.0" y="71" font-size="11" hoʻopiha="kala kala">No ka mea</kikokikona> <pololei x="127.6" y="62" laula="10" kiekie="10" hoʻopiha="#38bdf8" /> <kikokikona x="142.6" y="71" font-size="11" hoʻopiha="kala kala">Kūʻē</kikokikona> <pololei x="208.0" y="62" laula="10" kiekie="10" hoʻopiha="#a78bfa" /> <kikokikona x="223.0" y="71" font-size="11" hoʻopiha="kala kala">E hoole</kikokikona> <pololei x="79.0" y="129.0" laula="13.3" kiekie="148.0" hoʻopiha="#f97316" /> <kikokikona x="85.7" y="125.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">8</kikokikona> <pololei x="94.3" y="166.0" laula="13.3" kiekie="111.0" hoʻopiha="#38bdf8" /> <kikokikona x="101.0" y="162.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">6</kikokikona> <pololei x="109.7" y="258.5" laula="13.3" kiekie="18.5" hoʻopiha="#a78bfa" /> <kikokikona x="116.3" y="254.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">1</kikokikona> <kikokikona x="102.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="102.0" dy="0">BPC-157</tspan></kikokikona> <pololei x="139.0" y="129.0" laula="13.3" kiekie="148.0" hoʻopiha="#f97316" /> <kikokikona x="145.7" y="125.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">8</kikokikona> <pololei x="154.3" y="166.0" laula="13.3" kiekie="111.0" hoʻopiha="#38bdf8" /> <kikokikona x="161.0" y="162.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">6</kikokikona> <pololei x="169.7" y="258.5" laula="13.3" kiekie="18.5" hoʻopiha="#a78bfa" /> <kikokikona x="176.3" y="254.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">1</kikokikona> <kikokikona x="162.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="162.0" dy="0">KPV</tspan></kikokikona> <pololei x="199.0" y="129.0" laula="13.3" kiekie="148.0" hoʻopiha="#f97316" /> <kikokikona x="205.7" y="125.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">8</kikokikona> <pololei x="214.3" y="166.0" laula="13.3" kiekie="111.0" hoʻopiha="#38bdf8" /> <kikokikona x="221.0" y="162.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">6</kikokikona> <pololei x="229.7" y="258.5" laula="13.3" kiekie="18.5" hoʻopiha="#a78bfa" /> <kikokikona x="236.3" y="254.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">1</kikokikona> <kikokikona x="222.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="222.0" dy="0">TB-500</tspan></kikokikona> <pololei x="259.0" y="147.5" laula="13.3" kiekie="129.5" hoʻopiha="#f97316" /> <kikokikona x="265.7" y="143.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">7</kikokikona> <pololei x="274.3" y="184.5" laula="13.3" kiekie="92.5" hoʻopiha="#38bdf8" /> <kikokikona x="281.0" y="180.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">5</kikokikona> <pololei x="289.7" y="240.0" laula="13.3" kiekie="37.0" hoʻopiha="#a78bfa" /> <kikokikona x="296.3" y="236.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">2</kikokikona> <kikokikona x="282.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="282.0" dy="0">c-HUAOLELO</tspan></kikokikona> <pololei x="319.0" y="129.0" laula="13.3" kiekie="148.0" hoʻopiha="#f97316" /> <kikokikona x="325.7" y="125.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">8</kikokikona> <pololei x="334.3" y="184.5" laula="13.3" kiekie="92.5" hoʻopiha="#38bdf8" /> <kikokikona x="341.0" y="180.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">5</kikokikona> <pololei x="349.7" y="258.5" laula="13.3" kiekie="18.5" hoʻopiha="#a78bfa" /> <kikokikona x="356.3" y="254.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">1</kikokikona> <kikokikona x="342.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="342.0" dy="0">Mai hoʻolohe</tspan></kikokikona> <pololei x="379.0" y="147.5" laula="13.3" kiekie="129.5" hoʻopiha="#f97316" /> <kikokikona x="385.7" y="143.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">7</kikokikona> <pololei x="394.3" y="203.0" laula="13.3" kiekie="74.0" hoʻopiha="#38bdf8" /> <kikokikona x="401.0" y="199.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">4</kikokikona> <pololei x="409.7" y="258.5" laula="13.3" kiekie="18.5" hoʻopiha="#a78bfa" /> <kikokikona x="416.3" y="254.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">1</kikokikona> <kikokikona x="402.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="402.0" dy="0">Epitalona</tspan></kikokikona> <pololei x="439.0" y="166.0" laula="13.3" kiekie="111.0" hoʻopiha="#f97316" /> <kikokikona x="445.7" y="162.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">6</kikokikona> <pololei x="454.3" y="147.5" laula="13.3" kiekie="129.5" hoʻopiha="#38bdf8" /> <kikokikona x="461.0" y="143.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">7</kikokikona> <pololei x="469.7" y="258.5" laula="13.3" kiekie="18.5" hoʻopiha="#a78bfa" /> <kikokikona x="476.3" y="254.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">1</kikokikona> <kikokikona x="462.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="462.0" dy="0">Emideltide</tspan></kikokikona> <kikokikona x="280.0" y="366" heleuma kikokikona="waena" font-size="10" hoʻopiha="kā mākou(--pakuhi-muted, kala kala)">Puna: Bass Berry & ʻO Sims, makaʻala o ka mea kūʻai aku ma ke koho PCAC (2026-07-31)</kikokikona> </svg> </huahelu>

ʻOi aku ka liʻiliʻi o nā kiʻekiʻe ma mua o ko lākou ʻano. BPC-157, KPV a me TB-500 i lawe i 8-6 me 1 haʻalele; Lawe ʻo MOTS-c i 7–5 me 2 haʻalele; Semax 8–5 me 1 haʻalele; Epitalon 7–4 me 1 haʻalele. Ua hāʻule ʻo Emideltide me ʻeono no, ʻehiku kūʻē a hoʻokahi ʻaʻole (ka papa koho balota). ʻO nā palena mai ka 7-4 a hiki i ka 8-6, he komite i maheleia e hookahi a elua paha noho ma na mea i makemake ia e paipai.

Manaʻo ʻia ʻeono Peptides: He aha ka Iulai 2026 ʻO nā koho aʻoaʻo no ka mākaukau hōʻike

ʻAʻohe mea ma ka papa inoa. He aʻoaʻo nā balota, pono e apono maoli ke Kakauolelo HHS i kekahi hoohui, a ʻaʻole hiki i nā lāʻau lapaʻau ke hoʻohui i kēia mau peptides a hiki i ka hoʻokumu ʻana i nā lula hope loa, ʻoiai ma kahi e loaʻa ai ka API lāʻau lapaʻau (pharmacy trade coverage of the vote). Hana ʻia ka papa inoa e ka hoʻoponopono ma lalo o ka pauku 503A(c), e like me ka Hoolaha halawai Federal Register hoʻonohonoho, no laila, ʻo ka hoʻokomo ʻana he hana hoʻoponopono kānāwai ma mua o ka hana komite. ʻO ka heluhelu ʻana i ka helu ma ke ʻano he hoʻoholo ʻo ia ke ʻano hāʻule mua, a he hewa heluhelu, ʻaʻole kahi hoʻoponopono.

No ke aha i kūʻē ai nā kānaka ʻepekema limahana a FDA i nā peptides ʻeono?

Ua kau ʻia kēlā ʻōlelo hoʻokaʻawale ma luna o nā mea kūʻē a nā limahana FDA i kau i ka moʻolelo. Ua kūʻē nā limahana FDA i kēlā me kēia hoʻohui ma nā kumu ʻekolu: ʻaʻohe ʻikepili hoʻokolohua paʻa, nā ʻano hana like ʻole mai ka pūʻulu a i ka pūʻulu, a me ka pilikia o ka hoʻopilikia kino kino (hoike ana mai ka halawai). ʻElua o ia mau pilikia kemika. ʻO ka ʻokoʻa ʻole ʻana o ka puʻupuʻu he pilikia hoʻomalu hana, a me ka immunogenicity i loko o ka pōʻaiapili peptide ka nui o ka haumia a me ka pilikia aggregation, ʻo ia ke kumu Mea hoʻohuihui-palekana o FDA nā hae GHRP-2, GHRP-6, ipamorelin acetate a me kisspeptin-10 no ka pilikia immunogenicity "ma muli o ka hiki ke hoʻohui ʻia a me nā haumia pili i ka peptide."

Manaʻo ʻia ʻeono Peptides: He aha ka Iulai 2026 ʻO nā koho aʻoaʻo no ka mākaukau hōʻike

He lahilahi ka mooolelo kikoo, nā ala hiki ke nānā ʻia. Loaʻa nā peptides a pau koe ʻo TB-500 "ʻaʻole i hōʻike maikaʻi ʻia mai ka hiʻohiʻona o ke kino a me ke kemika"; ʻAʻole i loaʻa ka ʻike e pono ai no ka loiloi ʻana i nā hiʻohiʻona physicochemical i manaʻo ʻia e KPV; ʻAʻohe aʻo ʻana o Epitalon e loiloi ana i ka insomnia e ke ala subcutaneous i manaʻo ʻia; Aia ka noiʻi ʻo Semax i nā ʻiole wale nō, me ka ʻike ʻole hiki ke hoʻomāinoino. Ua ʻike ka poʻe loiloi i ka pilikia immunogenicity no nā ʻano injectable (ka nānā ʻana i ka ʻōlelo pōkole).

Ua hoʻopaʻapaʻa ʻia ka ʻike ponoʻī. Ua ʻike nā mea pōkole a FDA i nā inoa maʻamau ʻaʻole e hahai ana i nā hui USAN a i ʻole INN hiki ke wehewehe i nā ʻano hana like ʻole., a me kēlā kumu kūʻokoʻa, ʻokoʻa nā ʻano paʻakai a me nā ʻano ester o ka ʻāpana like i ka physicochemical, toxicological a pharmacokinetic hana, no laila, ʻaʻole ʻike pono ka inoa wale nō (ka §503A alahele kālailai). No BPC-157 kūikawā, kūʻai ʻia nā mea he nui ma lalo o ka inoa maʻamau me nā ʻāpana hana like ʻole, no laila "ʻaʻohe kumu hilinaʻi no ka hōʻoia ʻana i ka inoa i hāʻawi ʻia e ʻike mau i ke ʻano kemika like a me ke ʻano" (ka papa koho balota).

He kemika ia mau mea kue, ʻaʻole kikoʻī. ʻO kahi papahana e pane iā lākou e pane iā lākou me nā palapala, a ʻo nā waihona ʻeono ma lalo nei nā palapala.

ʻO ke ʻano ma ka papa inoa hoʻohuihui ʻo ia ka mea i ʻae ʻia kahi peptide, palekana, a maikaʻi paha?

ʻO ka loiloi bulks-list e noʻonoʻo i ke ʻano o ke kino a me ke kemika, palekana, hōʻike o ka pono a me ka hoʻohana mōʻaukala. ʻAʻole ia ke kaʻina hana apono lāʻau hou, akā hiki i nā hōʻike lapaʻau ke pili loa i ka pae palekana a me ka pono. ʻAʻole hoʻokumu ka papa inoa i ka ʻae FDA.

ʻOi aku ka liiki o nā ala kānāwai ma mua o ka manaʻo o ke poʻo. Pono ka huahana i hui ʻia i kahi monograph USP a i ʻole NF, a i ʻole kekahi lāʻau lāʻau i ʻāpana o ka lāʻau i ʻae ʻia e FDA, a i ʻole he wahi ma ka 503A Bulks List (ka Gku Peptide Hoolaha halawai Federal Register). ʻAʻole ʻae ʻia ka lāʻau lapaʻau ka maʻamau bulks-list: huli ka papa inoa i nā pae ʻehā, ʻaʻole ma nā hoʻokolohua e hōʻike ana i ka palekana a me ka pono (ka §503A alahele kālailai).

ʻO ke ʻano hoʻokele manawa kokoke i ka manaʻo hoʻokō manawa, hiki paha ke hoʻoneʻe i nā peptides i loko o ka Māhele 1 o ke kulekele bulks interim. ʻAʻole ia e hoʻololi i ke kānāwai, ʻaʻole ʻae i kekahi huahana, ʻaʻole e uhi i nā huahana noiʻi-hoʻohana wale, nā mea hoʻohui a i ʻole 503B outsourcing hale, ʻaʻole e hoʻopaʻa i nā papa mokuʻāina, a hiki ke hōʻemi a hoʻihoʻi ʻole ʻia me ka ʻole o ka ʻike (ka ʻOkakopa 2026 kālailai hoʻokō). ʻAʻole i hoʻomaha ka hoʻokō no ke koho balota: Ua hoʻopuka ʻo FDA i ʻelima mau leka hoʻomaopopo i nā mea kūʻai peptide pūnaewele ma 24 ʻAukake 2026, ka ʻike ʻana ʻaʻole i ʻoi aku ka nui o ka hōʻailona noiʻi-hoʻohana-wale i nā hōʻike o ka hoʻohana kanaka i manaʻo ʻia (ka ʻOkakopa 2026 kālailai hoʻokō).

ʻO nā pae hoʻohālikelike ʻehā he lens hoʻohana no ka palapala peptide CMC ma waho o ka hui ʻana, no ka mea, nīnau lākou i nā nīnau like a ka mea loiloi e nīnau ai i kekahi dossier. ʻO ka mea a lākou e hana ʻole ai, ʻo ia ke pani no ka moʻolelo analytical, kahi e noho ai na pauku eha.

He aha nā hōʻike ʻike e manaʻo ai ka FDA no kahi peptide, a me nā ʻano hana e helu ʻia?

Manaʻo ʻia ʻelua mau ala orthogonal, a ʻo ka hui pū ʻana e hōʻoia pono i ke kaʻina. Manaʻo ka EMA synthetic-peptide guideline ma kahi o ʻelua mau ʻano ʻike orthogonal no ka kikoʻī a me ka hoʻokuʻu., unuhi ʻia mai ka lehulehu, manawa paʻa pili, LC-MS, LC-MS/MS, palapala palapala peptide, bioactivity, ka nānā ʻana i ka waikawa amino a i ʻole NMR, me ke kuleana o ka mea noi no ka hōʻike ʻana i ka hui i koho ʻia e hōʻoia i ke kaʻina (ka EMA synthetic-peptide alakaʻi).

ʻO ke kumu kumu he ʻelemakule a ʻoi aku ka laulā. Pono nā ho'āʻo ʻike e kikoʻī loa a ma muli o nā ʻano kūʻokoʻa o ke ʻano molekala, a ʻoi aku ma mua o hoʻokahi hoʻokolohua, physicochemical, mea ola kino a i ʻole immunochemical, pono paha; Ua kapa ʻia ka hui ʻana o ka amino acid ma ke ʻano he ʻike kūkulu pono no nā peptides a me nā protein liʻiliʻi (I Q6B). Hoʻokuʻu ʻo ICH Q6B i nā peptides synthetic mai kāna kiko a hoʻopaneʻe i ke alakaʻi alakaʻi., akā, ʻo kāna loiloi ʻike ka mea e hoʻopili ai nā regulators.

Hoʻopaʻa ʻia ke ʻano hemahema. ʻO nā inoa mea hemahema maʻamau o FDA e hilinaʻi ana i hoʻokahi ala HPLC maʻamau a me nā piko i ʻike ʻia e ka manawa paʻa pili e like me ka hāʻule mau ʻana., a kuhikuhi iā UHPLC-HRMS/MS no ka ʻike kiʻekiʻe a me ka maʻemaʻe kiʻekiʻe (ʻO ka papa inoa o nā hemahema maʻamau o FDA). ʻO kahi hōʻoia nui hoʻokahi e pane i kahi nīnau ʻokoʻa ma mua o kahi kikoʻī.

Lawe ʻia kahi moʻolelo ʻike liʻiliʻi i ka mana kaʻina, ka N- a me C-terminus e like me ka synthesized, ke kahua hoʻololi a me kemika, ke ano kue, ka helu hailona, ka mea hoʻomaopopo i ke ʻano, kolamu, gradient a me ka hawewe ʻike, Hale Hana ʻIke Peptide a me ka maʻamau kuhikuhi i hoʻohana ʻia. Aia ka counterion i loko o kēlā papa inoa no ka mea ʻo ka peptide like me ke kumu manuahi a ʻo ka acetate ʻaʻole ia ka lāʻau lapaʻau like., a ua nānā ka hālāwai i nā ʻano ʻelua no kēlā me kēia mea.

Hōʻike ʻo MOL Changes i ka HPLC a me ka hoʻāʻo nui-spectrometric ma waena o kāna mau lawelawe. ʻAʻole hiki ke hoʻomaʻemaʻe ʻia ka maʻemaʻe ʻāpana HPLC me ka nui paʻa, iaia iho, hoʻokumu i ka ʻike kikoʻī, hoʻololi kikoʻī pūnaewele a i ʻole he pūʻolo ʻike orthogonal. E noi i nā ʻano hana a me nā hōʻike e pono ai no ke kūkulu ʻana a me ka hoʻohana i manaʻo ʻia.

No ke aha i lawa ʻole ai ka pākēneka maʻemaʻe HPLC hoʻokahi, a he aha hou aku e ana?

Maemae, ʻike ʻike, ʻEhā ana ka ʻike a me ka haumia, a ʻo kahi helu pākēneka e pane i kahi hapa o hoʻokahi. He paʻakikī ka hoʻomaʻemaʻe piha ʻana a pili nā hopena, no laila ua manaʻo ʻia ka maʻemaʻe e ka hui pū ʻana o nā ʻano hana ma mua o kahi chromatogram hoʻokahi (ʻO ka wehewehe ʻana o ICH Q6B o ka maʻemaʻe). Hoʻokaʻawale ka ICH Q6B i nā ala maʻemaʻe mai nā ʻano haumia, ʻo ia ke kumu ʻaʻole hiki i hoʻokahi helu ke lawelawe ma ke ʻano he kikoʻī.

ʻOkoʻa nā paepae ma muli o ke aupuni, a okoa ke kaupaona kanawai me lakou. No nā peptides synthetic, ka Ph. Eur. ʻO ka monograph maʻamau e pili ana i nā mea no ka hoʻohana lāʻau i hoʻonohonoho i nā haumia pili i ka peptide e hōʻike ʻia ma luna. 0.1%, i ʻike ʻia ma luna 0.5% a kūpono ma luna 1.0%, a pili ka EMA i nā paepae like i nā huahana i hoʻopau ʻia (ka EMA synthetic-peptide alakaʻi). I Q3A(R2) hoʻonohonoho i nā waiwai like ʻole no nā mea haumia lāʻau lapaʻau ma ka nui o kēlā me kēia lā 2 g/lā a emi mai paha: hōʻike 0.05%, ʻike ʻike 0.10% a i ʻole 1.0 mg / lā i ka mea haʻahaʻa, kūpono 0.15% a i ʻole 1.0 mg / lā (I Q3A(R2) hōʻike a me nā paepae hōʻoia). Hōʻike ke alakaʻi EMA e kāpae ʻia nā peptides synthetic mai ICH Q3A a ʻaʻole pili kona mau palena., no laila ʻaʻole hiki ke hoʻololi ʻia nā alapiʻi ʻelua.

Ke alakaʻi kikoʻī kikoʻī a FDA no ka semaglutide, hooponopono hou ia ma Iulai 2026, hoʻohana i ka 0.1% a 0.5% hōʻike a ʻike i nā huahelu akā hoʻohui i kahi hōʻailona pili: ʻAʻole pono kēlā me kēia haumia e ʻoi aku ma mua o ka pae o ka lāʻau lapaʻau i helu ʻia a i ʻole 1.0%, ka mea i oi aku, pono e hoemiia na mea haumia hou malalo 1.0%, a ʻaʻole pono e ʻoi aku ka nui o nā mea haumia e pili ana i ka mea hana ma mua o ka huahana kuhikuhi (ka lulai 2026 kahakiʻi i ke alakaʻi kikoʻī huahana). Ua kaha 'ia ka palapala no ka ho'okō 'ana, a he huahana-specific ia, no laila ʻaʻole ia e kau i kahi palena peptide maʻamau.

ʻO ke alakaʻi peptide EU a me kahi kiʻi kikoʻī kikoʻī US semaglutide he mau ʻokoʻa like ʻole. E noʻonoʻo i ka huahana maoli a me nā pae hoʻomaʻemaʻe; ʻaʻole ka palena hoʻokuʻu ʻana i ka hōʻike a i ʻole ka paepae hōʻoia, a ʻaʻole hiki i ka hoʻohālikelike semaglutide ke wehewehe i ka ʻae ʻana o US i kēlā me kēia peptide.

Pehea ʻoe e hōʻoia ai i ka nui-a-lot reproducibility a me ke ʻano hōʻike kūpaʻa?

Hōʻike ʻia ka reproducibility e kahi moʻolelo hīnaʻi pili a me kahi ala i hōʻike ʻia e ʻike i ka hoʻohaʻahaʻa, ʻaʻole ma nā palapala hōʻoia ʻekolu e hōʻike ana kēlā me kēia i kahi pākēneka kiʻekiʻe. Pono ke alakaʻi EMA e aʻo ʻia nā waiwai hōʻike kūpaʻa a me ke koena nui o ke ʻano, a mālama i ka loaʻa ʻana o nā ala e hōʻike i ka kūpaʻa me ka hoʻonā kiʻekiʻe maikaʻi a me ke koena nuipa maikaʻi ma ke ʻano he koi. (ka EMA synthetic-peptide alakaʻi). Pono nā haʻawina hoʻohaʻahaʻa ikaika e hōʻike i ka degradation o ka peptide a me ka hiki o ke kaʻina hana analytical e ʻike ai..

Hana nā peptide i kēlā koi. Hoʻomaopopo ke alakaʻi like i nā peptides e lilo i thermally labile, no laila e ʻike ʻia ka hoʻohaʻahaʻa ʻana i nā kūlana mālama kūpono ʻole, a ua papa inoa ia i ka oxidation o Cys a me Met koena, deamidation, hydrolysis a me nā kaʻina beta-Asp e like me nā ala hoʻohaʻahaʻa e kūkākūkā ai (ka EMA synthetic-peptide alakaʻi). Pono e noiʻi ʻia ka hoʻokumu ʻana o nā haumia kiʻekiʻe-molecular-kaumaha i ka wā paʻa inā pili. Hale Hana Peptide P

Loaʻa i ka hōʻoia kona ʻīpuka ponoʻī. Pono kahi kaʻina hana haumia quantitative i ka kikoʻī, he laulā me ka palena haʻahaʻa ma ka palena helu, pololei a pololei, a me kahi protocol hōʻoia e hōʻike ana i ke kumu i manaʻo ʻia, Pono nā hiʻohiʻona a me nā pae hoʻohālikelike ma mua o ke aʻo ʻana (I Q2(R2) Papakaukau 1). ʻAʻole hoʻohui ke alakaʻi EMA i nā koi hōʻoia ʻē aʻe ma mua o kēlā no nā mea hana kemika ʻē aʻe.

No kahi papahana noiʻi, ʻo ka manaʻolana kūpaʻa ua kūpono ka pae ma mua o ka hopena. Pono ka ʻikepili kūpaʻa ma nā ʻāpana āpau e hōʻike i ka noho ʻana o ka mea i loko o nā kemika a me nā palena kino kūpono no ka lōʻihi i hoʻolālā ʻia., a ma kahi e ho'āʻo ʻia ai ka wā pōkole loa, hiki ke kaupalena ʻia nā ʻikepili kākoʻo (21 CFR 312.23).

ʻO kahi moʻolelo hailona pili e like me kēia: helu hailona, ka chromatogram me ka mea hoʻomaopopo a me ka maʻamau kuhikuhi, ʻO ka hopena hoʻohaʻahaʻa ikaika e hōʻike ana i ke ala e hoʻonā ai i nā mea hoʻohaʻahaʻa, a me ka protocol stability me kona kūlana mālama a me nā manawa. ʻO Scale-up kahi e haki ai ka moʻolelo, no ka mea, pono e hoʻohālikelike ʻia kahi ʻike haumia i ʻike ʻia i loko o nā pailaka a i ʻole nā ​​​​hui kalepa me ka ʻikepili mua a me kona hopena i ka maikaʻi a me ka ʻikepili lapaʻau a me ka preclinical i kūkākūkā ʻia. (ka EMA synthetic-peptide alakaʻi).

He aha ka lāʻau lapaʻau lapaʻau a me nā palapala lapaʻau e pono ai kahi peptide ma mua o kahi kamaʻilio pre-IND?

ʻO ka moʻolelo lapaʻau ka puka nāwaliwali loa a ʻo ia ka mea e hoʻonohonoho i ka manawa, no ka mea hiki ke kūkulu hou ʻia ka pūʻolo analytical ma mua o ka hiki ke hana ʻia ka ʻikepili kanaka. ʻAʻole i loaʻa i nā loiloi ponoʻī o FDA kahi pae paʻa 3 nā hoʻokolohua randomized ma waena o nā peptides ʻeono i manaʻo ʻia, a nānā i ʻelima mau hoʻokolohua kanaka liʻiliʻi no BPC-157 (ka hoike komite-komo). Waiwai Peptide

ʻOi aku ka lahilahi o ka tally per-peptide ma mua o ka manaʻo o ka balota. He emi mai 36 nā kumuhana kanaka a puni 3 kākoʻo nā haʻawina i ka BPC-157, i loko o kahi haʻawina hoʻopaneʻe kuli 16-kumu, he 12-ma'i ma'i ho'okohu ma'i ma'i a me 2-kumuhana infusion ha'awina, me nā holoholona hōʻike BPC-157 ʻē aʻe; KPV, ʻO MOTS-c a me TB-500 ka nele o nā haʻawina i nā kānaka ma kekahi ala; Ua kaupalena ʻia ka ʻikepili Semax i nā haʻawina kūpono ʻole i hana ʻia ma waho a ʻaʻole ma lalo o kahi IND; Ua holo nā hoʻokolohua kanaka Epitalon ma Rūsia a me Ukraine ma waho o ka mālama FDA a i ʻole ka hoʻomaʻamaʻa lapaʻau maikaʻi ʻo ICH (he ʻōlelo hoʻopuka e hoʻonui i ka ʻikepili kanaka).

ʻO nā manaʻolana o ka lāʻau lapaʻau he peptide-specific a aia mau i ka draft. ʻO ke alakaʻi hoʻolālā a FDA no ka lāʻau lapaʻau lapaʻau no nā huahana lāʻau peptide, hoʻopuka ʻia ʻo Dekemaba 2023 a hōʻailona ʻia ʻaʻole no ka hoʻokō, mālama i ka maʻi hepatic, pili lāʻau lāʻau, QTc hoʻolōʻihi i ka pilikia a me ka immunogenicity pilikia e like me ka peptide-specific considerations (ʻO ka papa kuhikuhi peptide clinical pharmacology alakaʻi a FDA). ʻO nā ʻōlelo a ka ʻoihana i ka docket ke hoʻopaʻapaʻa nei he haʻahaʻa haʻahaʻa ka pili ʻana o ka lāʻau lapaʻau me ka peptides., ʻAʻole maʻamau ka CYP-metabolized nā peptides, a ʻaʻole lawa ka biomarker hoʻokahi, me ʻelua a ʻoi aʻe paha e kākoʻo ana i ka hoʻomaopopo ʻana i ka palekana a me ka pono (nā ʻōlelo a ka ʻoihana i ka docket). He mau kūlana ʻaoʻao kākoʻo kēlā, 'a'ole koi 'oihana.

Aia ke ala kaʻina hana. ʻO kahi hālāwai pre-IND he ʻano hui hui B i ʻike ʻia ma lalo o ke kaʻina hui hui kūikawā a FDA no nā huahana PDUFA. (ʻO ke alakaʻi alakaʻi o ka PDUFA o ka FDA). ʻO ka mea i hana ʻole ʻia e nā lula e hoʻonohonoho i ka ʻikepili kikoʻī peptide: 21 CFR 312.23 koi i nā palena kūpono a me nā ʻano analytical no ka ʻike, ikaika, maikaʻi a me ka maʻemaʻe, a ʻōlelo ʻia ʻaʻole manaʻo ʻia nā kikoʻī hope loa a hiki i ka pau ʻana o ke kaʻina hoʻokolokolo (21 CFR 312.23). ʻAʻole kēia ʻatikala he ʻōlelo aʻoaʻo hoʻoponopono; pono e hōʻoia ka papahana i kāna pūʻolo e kūʻē i ke alakaʻi o kēia manawa a me FDA pololei.

Pehea e hui pū ai nā kāʻei kapu ʻeono i hoʻokahi hoʻoholo mākaukau?

Hoʻokumu ʻia nā kikowaena ʻeono i ke kaʻina o nā ʻīpuka, a ʻo ka ʻīpuka nāwaliwali loa e hoʻonohonoho i ka palena manawa ma mua o ka awelika. ʻO ka ʻīpuka ka ʻike: ma ka liʻiliʻi ʻelua mau ʻano orthogonal nona ka hui ʻana e hōʻoia i ke kaʻina (ka EMA synthetic-peptide alakaʻi). ʻO ka puka ʻelua ka maʻemaʻe a me ke koena nuipa, me kahi ʻano hōʻike kūpaʻa i ʻike maoli ʻia nā huahana degradation. ʻO ka puka ʻekolu ka ʻike haumia i lawe ʻia i ka paepae kūpono, me ka co-eluting peaks i hoʻoholo ʻia a i ʻole ka merged peak qualified.

E noʻonoʻo i ka mōʻaukala pūʻulu me kahi hoʻohālike kūpono a me ka hoʻolālā hoʻohālikelike. Q2(R2) ʻōlelo i ka hōʻoia analytical-procedure; ʻaʻole ia he kaʻina-hōʻoia a i ʻole ka helu helu helu.

E nānā i nā leka hoʻomaopopo FDA no kekahi hālāwai aʻoaʻo peptide hou aʻe a me kāna papahana. ʻAʻole he loiloi piha ka puka makani hālāwai wānana a i ʻole he lā kulekele i hōʻoia ʻia.

Nīnau pinepine

Ua hana ʻo Iulai 2026 koho e hoʻohui i kēia mau peptides i ka 503A Bulks List?

ʻAʻole. Ua paipai ke komite eono o ehiku, a ʻo ka ʻōlelo aʻoaʻo. Loaʻa ka mea i ka papa inoa ma o ka hoʻolaha ʻana a me ka manaʻo kānāwai ma lalo o ka pauku 503A(c), a hiki i ka puka ʻana o kahi lula hope, ʻO ka hui pū ʻana i kēia mau peptides e noho ana ma waho o ke awa palekana 503A (ka hoʻolaha hālāwai Federal Register).

He a 98% Loaʻa ka hopena maʻemaʻe HPLC no kahi kikoʻī peptide?

ʻAʻole. ʻO ka maʻemaʻe e pili ana i ke ʻano a ua manaʻo ʻia e ka hui pū ʻana o nā ʻano hana, a me ICH Q6B papa inoa i nā ʻano hana maʻemaʻe mai nā ʻano haumia (ʻO ka wehewehe ʻana o ICH Q6B o ka maʻemaʻe). Pono pū kekahi kikoʻī i ka ʻike ma o ʻelua mau ʻano orthogonal, he palapala haumia i ka paepae pili, maʻiʻo ma ke kumu anhydrous counterion-free, a me ke ʻano hōʻike kūpaʻa.

ʻO nā paepae haumia e pili ana i kahi peptide synthetic?

Pili ia i ke aupuni. ʻO ka Ph. Eur. ʻO nā paepae i hōʻike hou ʻia ma ke alakaʻi EMA i hōʻike ʻia ma luna 0.1%, hoʻomaopopo ma luna 0.5% a kūpono i luna 1.0% (ka EMA synthetic-peptide alakaʻi). I Q3A(R2) hoʻonohonoho 0.05%, 0.10% a 0.15% i ka nui loa o kēlā me kēia lā o 2 g/lā a emi mai paha, a ua ʻōlelo ke alakaʻi EMA ʻaʻole pili kēlā mau palena i nā peptides synthetic (I Q3A(R2) hōʻike a me nā paepae hōʻoia).

ʻAʻole i ʻike ʻia e nā loiloi FDA ʻaʻole i hoʻopau ʻia ka pae 3 nā hoʻokolohua randomized ma waena o nā ʻeono (ka hoike komite-komo). ʻOi aku ka liʻiliʻi o ka manaʻo palapala 36 nā kumuhana a puni 3 Nā haʻawina BPC-157, ʻaʻohe haʻawina hoʻokele kanaka no KPV, MOTS-c a i ʻole TB-500, a me nā haʻawina haole no Semax a me Epitalon i hana ʻia ma waho o kahi IND a i ʻole ICH-harmonized hoʻomaʻamaʻa lapaʻau maikaʻi (he ʻōlelo hoʻopuka e hoʻonui i ka ʻikepili kanaka).

Ka hopena

He ʻōlelo hoʻokaʻawale ʻia ke koho balota ma nā pae kānāwai ʻehā, a ʻo nā mea kūʻē ma hope o ka māhele ʻana he kemika a me ka palapala: ʻike i hiki ʻole i ka inoa ke hōʻoiaʻiʻo, nā ʻaoʻao haumia ʻaʻole hiki i kahi chromatogram ke hoʻokumu, ʻano like ʻole pūʻulu, a he moʻolelo lapaʻau ʻaʻole i loaʻa i ka hapa nui o nā hihia. Hoʻololi ka nānā ʻeono-domain i kēlā mau kūʻē i kahi papa hana, a me ka puka nawaliwali loa, palapala maʻamau maʻamau, hoʻonohonoho i ka palena manawa.

ʻO ka hana aʻe e holo i nā ʻīpuka ʻeono e kūʻē i kahi kaʻina a hoʻopaʻa i kahi i kū ai ka hōʻike. He polokalamu hiki ke hōʻike i kona ʻano ʻike, kona mau paepae haumia a me ko lakou kaumaha kanawai, kona hopena hoʻohaʻahaʻa ikaika, ʻO kona mōʻaukala nui a me kāna kūlana ʻikepili kanaka i ka pūʻolo FDA i ʻōlelo ʻia e nalo nei, a aia ia ma mua o ka hiki ʻana o ka lua o nā koho i ke komite.

Hōʻike ka mea hoʻopuka: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a he hoihoi koʻikoʻi i kēia kumuhana. ʻO nā lālā lawelawe a me nā ʻōlelo hiki ke koi i nā mea hoʻolako; ʻO ka loaʻa a me ka hana ʻana no kahi kūkulu kikoʻī e koi i nā hōʻike kikoʻī o ka papahana.

Xiaoxia Chen

Xiaoxia Chen

Laau Laau Hou R&D ʻenehana Kaʻike kumu: Loaʻa ka pahuhopu, pilina hana-hana (SAR) kālailai, peptide-lāʻau conjugates (Nā PDC), a me ka hoʻomohala ʻana i nā peptides anti-kahiko a me ka metabolic.

Pilikino: Ua alakaʻi ʻo Xiaoxia Chen i ka ʻike mua ʻana a me ka noiʻi preclinical no kekahi mau lāʻau peptide metabolic a me ka tumor-targeted.. ʻAʻole wale ʻo ia i mākaukau i ka nānā ʻana i nā hale waihona puke peptide, akā akamai nō hoʻi i ka hoʻohana ʻana i ka biology computational kōkua AI no ka hoʻolālā ʻana o ka de novo peptide sequence.. I kēia manawa, ke alakaʻi nei ʻo ia i kahi hui i hoʻolaʻa ʻia i ka noiʻi hohonu a me ka hoʻomohala ʻana o nā agonists multifunctional hanauna hou (like me pālua- a i ʻole nā ​​peptides hoʻohaʻahaʻa momona ʻekolu) a me nā peptides hoʻoponopono hou i ke kino.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana